|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Fr.III cells expressed high levels of ICOS and CD154, but a low level of Tfr and BACH2, BACH2 expression was negatively correlated with SLE Disease Activity Index.
|
31808546 |
2020 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
Genetic and functional data suggested the CD40 receptor (CD40) and CD40 ligand (CD40L) as strong candidate genes for SLE.
|
30374748 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
Upon stimulation of B cells with IL-2/IL-10, anti-BCR, CpG, and CD40L for 48 hours, the capacity of SLE B cells to up-regulate PD-L1 expression was substantially diminished (P = 0.0006) along with reduced B cell proliferation (P = 0.0039).
|
30919595 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analyses found associations between <i>CD40</i> rs4810495, rs1883832, and rs376545 polymorphisms and systemic lupus erythematosus susceptibility and significantly higher sCD40 and sCD40L levels in patients with systemic lupus erythematosus than in controls.
|
31570051 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
The CD40-CD40L pathway is a promising treatment target for autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and lupus nephritis.
|
29127458 |
2018 |
|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Elevated levels of soluble CD40 ligand are associated with antiphospholipid antibodies in patients with systemic lupus erythematosus.
|
28421990 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Strikingly, an autoreactivity profile defined by IgG anti-Ro/La was associated with reduced levels of specific natural IgM targeting phosphorylcholine (PC) antigens and malondialdehyde (MDA) modified-protein, as well as total IgM, while no differences were detected in SLE patients with an autoreactivity profile defined by anti-cardiolipin/β<sub>2</sub>glycoprotein-I.
|
28919518 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
Because hydroxychloroquine (HCQ) has been used frequently in the treatment of lupus, we sought to identify the effects of HCQ on CD154 and a possibly regulatory mechanism.
|
28793932 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Association study of CD154 polymorphisms and serum CD154 level with systemic lupus erythematous in Chinese population.
|
28550400 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
Current evidence shows that the CD40-CD40L system plays a crucial role in the development, progression and outcome of SLE.
|
26289938 |
2016 |
|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In this work, we investigated the implication of miR-21 in the experimentally inducible bm12→B6 cGVHD model of systemic lupus erythematosus (SLE). cGVHD host mice deficient in miR-21 show a 2-fold reduction in splenomegaly, significantly reduced autoantibody titers and down-regulated components of the CD40:CD40L and CD28:CD80/86 co-stimulation pathways.
|
26631756 |
2016 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
Compared with the normal control group, the expressions of PKCδ, ERK1/2, CD11a, CD70 and CD40L increased, but DNA methylation levels of CD11a, CD70 and CD40L decreased in the SLE control and RA control groups.
|
27915349 |
2016 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
These data suggest that the presence of two X chromosomes may predispose to SLE, the ligand (CD40 ligand) for one of the genes that contributes to the pathogenesis of SLE being located on the X chromosome.
|
26936892 |
2016 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
Polymorphisms in several genes were associated with IL-6 levels (including IL10, TYK2, and CD40L in SLE and DRB1, NOD2, and CSF1 in RA) or with TNFα levels (including TNFSF4 and CSF2 in SLE and PTPN2, DRB1, and NOD2 in RA).
|
25652333 |
2015 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
This activity was inhibited by anti-CD40L antibody, as well as anti-CD1d antibody, confirming a role for CD40L-CD40 and TCR-CD1d interactions in lupus iNKT-cell-mediated help.
|
25352488 |
2015 |
|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Thus, these findings provide some of the first evidence to support a possible mechanistic link to explain how the overexpression of IL-15 observed in lupus patients may be involved in the prolonged expression of CD154 that has also been observed on lupus CD4 T cells.
|
24500400 |
2014 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
Epigenetic deregulation of genes encoded on the X chromosome as reported for CD40L in lupus could explain the female predominance of autoimmune diseases.
|
24117612 |
2014 |
|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We determined PECAM-1 polymorphisms, soluble PECAM-1, and CD40L levels in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) and evaluated their associations with clinical atherosclerotic complications.
|
25201689 |
2014 |
|
Lupus Erythematosus, Systemic
|
0.300 |
PosttranslationalModification
|
disease |
BEFREE |
Apart from those classic methylation-sensitive autoimmunity-related genes in lupus, such as CD11a (ITGAL), Perforin (PRF1), CD70 (TNFSF7), CD40 ligand (TNFSF5) and PP2Acα, the genome-wide methylation pattern has also been explored recently, providing us a more and more full-scale picture of the abnormal status of DNA methylation in SLE.
|
23340289 |
2013 |
|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
This suggests that demethylation of genes on the inactive X may predispose women to lupus, and this hypothesis is supported by a report that CD40LG, an immune gene encoded on the X chromosome, demethylates and is overexpressed in T cells from women but not men with lupus.
|
23434382 |
2013 |
|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our data provide evidence that E4BP4 can inhibit CD40L expression through epigenetic modifications in the promoter region of CD40L, thus negatively regulating self-reactivity of SLE CD4(+) T cells.
|
23340290 |
2013 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
We have previously demonstrated that DNA demethylation of CD40L on the X chromosome is responsible for female susceptibility to systemic lupus erythematosus (SLE).
|
22889643 |
2012 |
|
Lupus Erythematosus, Systemic
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In systemic lupus erythematosus (SLE) sustained CD40L expression by T cells and platelets activates a variety of cells via its receptor CD40 contributing to disease pathogenesis.
|
21914625 |
2011 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
Systemic lupus erythematosus (SLE) is a heterogeneous disease involving several immune cell types and pro-inflammatory signals, including the one triggered by binding of CD40L to the receptor CD40.
|
21415255 |
2011 |
|
Lupus Erythematosus, Systemic
|
0.300 |
Biomarker
|
disease |
BEFREE |
Anti-CD40L immunotherapy in systemic lupus erythematosus patients was associated with thromboembolism of unknown cause.
|
20585032 |
2010 |